Korean Circ J.  2019 Feb;49(2):192-193. 10.4070/kcj.2018.0460.

Infliximab, Is It Really a New Horizon for the Treatment of Kawasaki Disease?

• Eun LY

• KMID: 2432138
• DOI: http://doi.org/10.4070/kcj.2018.0460

Abstract

No abstract available.

MeSH Terms

Infliximab*
Mucocutaneous Lymph Node Syndrome*
Infliximab

Reference

1. Han JW. The efficacy and safety of high-dose intravenous immunoglobulin in the treatment of Kawasaki disease: how can we predict resistance to intravenous immunoglobulin treatment of Kawasaki disease? Korean Circ J. 2017; 47:179–181.

2. Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol. 2015; 11:819–825.

3. Negi VS, Elluru S, Sibéril S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007; 27:233–245.

4. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011; 7:349–359.

5. Kim SJ. Risk factors related to coronary artery outcome in Kawasaki disease. Korean Circ J. 2018; 48:329–331.

6. Hur G, Song MS, Sohn S, et al. Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea. Korean Circ J. 2019; 49:183–191.

7. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005; 146:662–667.

8. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014; 383:1731–1738.

9. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998; 17:1144–1148.

10. Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017; 152:1901–1914.e3.